Current Metabolomics
Title:Editorial
Volume: 2 Issue: 1
Author(s): Robert Powers
Affiliation:
Export Options
About this article
Cite this article as:
Powers Robert, Editorial, Current Metabolomics 2014; 2 (1) . https://dx.doi.org/10.2174/2213235X0201140422152244
DOI https://dx.doi.org/10.2174/2213235X0201140422152244 |
Print ISSN 2213-235X |
Publisher Name Bentham Science Publisher |
Online ISSN 2213-2368 |
26
Related Articles
-
A Bioinformatics Pipeline for Cancer Epigenetics
Current Bioinformatics Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Matrix Metalloproteinases
Current Medicinal Chemistry Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets One Hundred Faces of Cyclopamine
Current Pharmaceutical Design TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Current Medical Imaging Podocytes as Target of Vitamin D
Current Diabetes Reviews In vitro Evaluation of Gadolinium-Silica Mesoporous Nanoparticles- Monoclonal Antibody: Potential Nanoprobe for Prostate Cancer Cell Imaging
Current Molecular Imaging (Discontinued) Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers Drug Evolution Concept in Drug Design: 2. Chimera Method
Medicinal Chemistry AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers
Current Pharmaceutical Biotechnology In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells
Current Cancer Drug Targets Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial
Reviews on Recent Clinical Trials Lipid Based Nanosystems for Curcumin: Past, Present and Future
Current Pharmaceutical Design Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design